RNA polymerase as an antiviral target of hepatitis C virus.

Hepatitis C virus (HCV) infection is emerging as one of the most prevalent viral diseases of medical significance. It afflicts approximately 100 million people worldwide. Although HCV infections are mostly clinically inapparent during the acute stage, the majority of infected patients develop chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. Mainly as a result of ongoing HCV epidemics, the incidence of hepatocellular carcinoma and demands for liver transplantation have increased at a rapid pace in many countries in the last couple of decades. The current therapeutic options for HCV are limited; interferon-alpha (IFN-alpha) alone or IFN plus ribavirin are the only available treatments. Unfortunately, these treatments are efficacious for only a limited number of patients. They are particularly ineffective against genotype 1 HCV, which is the most common genotype in developed countries, including most European countries, the USA and Japan. Therefore, the development of new therapeutic strategies is urgently needed, so that the progression of hepatic diseases in HCV-infected patients can be halted before serious late-stage illnesses manifest themselves. Otherwise, HCV may exact a huge toll on health care budgets and the wellbeing of societies in the ensuing decades.